KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ionis Pharmaceuticals (IONS) Total Liabilities (2016 - 2025)

Ionis Pharmaceuticals (IONS) has 17 years of Total Liabilities data on record, last reported at $2.4 billion in Q3 2025.

  • For Q3 2025, Total Liabilities changed 0.14% year-over-year to $2.4 billion; the TTM value through Sep 2025 reached $2.4 billion, changed 0.14%, while the annual FY2024 figure was $2.4 billion, 7.22% down from the prior year.
  • Total Liabilities reached $2.4 billion in Q3 2025 per IONS's latest filing, up from $2.4 billion in the prior quarter.
  • Across five years, Total Liabilities topped out at $2.6 billion in Q3 2023 and bottomed at $1.6 billion in Q1 2021.
  • Average Total Liabilities over 5 years is $2.2 billion, with a median of $2.4 billion recorded in 2025.
  • Peak YoY movement for Total Liabilities: skyrocketed 43.28% in 2023, then dropped 7.63% in 2024.
  • A 5-year view of Total Liabilities shows it stood at $1.8 billion in 2021, then rose by 6.58% to $2.0 billion in 2022, then surged by 32.76% to $2.6 billion in 2023, then dropped by 7.22% to $2.4 billion in 2024, then dropped by 0.01% to $2.4 billion in 2025.
  • Per Business Quant database, its latest 3 readings for Total Liabilities were $2.4 billion in Q3 2025, $2.4 billion in Q2 2025, and $2.3 billion in Q1 2025.